Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial

Jensen, Simon Birk Kjær; Blond, Martin Bæk; Sandsdal, Rasmus Michael; Olsen, Lisa Møller; Juhl, Christian Rimer; Lundgren, Julie Rehné; Janus, Charlotte; Stallknecht, Bente Merete; Holst, Jens Juul; Madsbad, Sten; Torekov, Signe Sørensen

doi:10.1016/j.eclinm.2024.102475

Cited by 16 publications

(5 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 47 , 48 Similarly, the S-LITE and SURMOUNT-4 trials also reported weight regain following the discontinuation of liraglutide and tirzepatide, respectively. 49 , 50 This was supported by an observational study, albeit in people living with diabetes, that reported an increased risk of CVD events in those who withdrew GLP-1 RAs. 51 …”

Section: Discussionmentioning

confidence: 86%

GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study

Moll,

Frey,

Gerber

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 86%

GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study

Moll,

Frey,

Gerber

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

“…26 Studies have also shown the improved effectiveness of weight maintenance when combining behavioral interventions with anti-obesity medications. 27 , 28 In the example scenario where the alternative maintenance program is half the price of continuous full-dose IMs and 30% as effective (ie, patients regain 70% of their weight and lose 70% of the long-term clinical benefit), a net lifetime savings of $35 100 results. The savings from each person switching to this lower-cost maintenance program would fund approximately 6 additional individuals to receive full-dose GLP-1/IM therapy for 1 year.…”

Section: Discussionmentioning

confidence: 99%

Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program

Kim,

Hwang,

Fendrick

2024

Health Affairs Scholar

View full text Add to dashboard Cite

Despite remarkable clinical advances in highly effective anti-obesity medications, their high price and potential budget impact pose a major challenge in balancing equitable access and affordability. While most attention has been focused on the amount of weight loss achieved, less consideration has been paid to interventions to sustain weight loss after an individual stops losing weight. Using a policy simulation model, we quantified the impact of a weight maintenance program following the weight loss plateau from the initial full-dose GLP-1s or incretin mimetic use on long-term health care savings and the loss of some health benefits (e.g., maintenance of weight loss, improvements in cardiometabolic risk factors, and reductions in diabetes and cardiovascular events). Our model suggested that compared to continuous long-term full-dose GLP-1s or incretin mimetic drugs, the alternative weight maintenance program would generate slightly fewer clinical benefits while generating substantial savings in lifetime health care spending. Using less expensive and potentially less effective alternative weight maintenance programs may provide additional headroom to expand access to anti-obesity medications during the active weight-loss phase without increasing total health care spending.

show abstract

“…Our study found that the willingness to purchase an innovative fruit and cereal bar with health-promoting properties would be higher if its packaging stated that it “helps to maintain a healthy body weight”. Normal body weight contributes to maintaining good health and feelings of being satisfied with life [ 61 ]. It is most often obtained through physical activity and proper nutrition [ 62 ].…”

Section: Discussionmentioning

confidence: 99%

Consumer Perception of Innovative Fruit and Cereal Bars—Current and Future Perspectives

Kosicka-Gębska,

Sajdakowska,

Jeżewska-Zychowicz

et al. 2024

Nutrients

View full text Add to dashboard Cite

The aim of the study was to ascertain consumers’ interest in innovative fruit and cereal bars and their expectations of changes that could be applied by manufacturers to improve their health-promoting properties. An additional aim was to assess how these interests and expectations, as well as the information provided on the product label, determine the willingness to purchase a fruit and cereal bar with health-promoting properties. Data were collected through a quantitative CAWI survey conducted in 2020. It involved 1034 respondents. A logistic regression model was developed in which the dependent variable was the respondents’ interest in an innovative fruit and cereal bar on whose packaging the manufacturer declared its health-promoting properties. It was found that producers’ efforts to change the packaging to an organic one (OR = 1.24) along with enriching the product with chia seeds/flaxseed (OR = 1.22), vitamins and minerals (OR = 1.19), as well as fruit (OR = 1.14) and protein (OR = 1.12), or removing ingredients that cause allergies, would significantly increase the chance of respondents purchasing such a bar. A celebrity image and a claim that the product “helps maintain a healthy body weight” on the label would also encourage purchases. On the other hand, reducing the sugar content or enriching a fruit and cereal bar with powdered insects would significantly reduce the propensity to buy it.

show abstract

Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: a post-treatment analysis of a randomised placebo-controlled trial

Cited by 16 publications

References 41 publications

GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study

GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit–harm modelling study

Balancing innovation and affordability in anti-obesity medications: the role of an alternative weight-maintenance program

Consumer Perception of Innovative Fruit and Cereal Bars—Current and Future Perspectives

Contact Info

Product

Resources

About